DIA Asia 2021-The Evolution Of Clinical Trials And Regulatory Science In A Post-Pandemic Digital World In Asia

The growth potential of Asia pharmaceutical and life science industries is astounding over the past few years and this sector is poised for growth. Despite Asia being a collection of markets with very diverse sets of regulatory environments, demographics, economic impact and disease profiles, Asia eco-system is investing in its capabilities to advance patient centricity and expectations of healthcare and life science experience. The scientific and technological developments in cell and gene therapies, mRNA, digital analytics capabilities, patient centric delivery, smart health devices are changing the current business models and driving cross-sector economy. In this plenary, we will review how the bioventures, mega pharmas, small startups collaborate with governments and regulators to build an innovative and sustainable ecosystem, so as to support the transformation into a patient centric, valued focused research landscape.